• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Zoltan Szallasi, MD


  • Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Grönroos E, Endesfelder D, Joshi T, Mouradov D, Gibbs P, Ward RL, Hawkins NJ, Szallasi Z, Sieber OM, Swanton C.Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.Cancer Discovery. 2014 Feb;4(2):175-85.
  • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.PLoS ONE. 2013;8(11):e80023.
  • Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C.Parallel evolution of tumour subclones mimics diversity between tumours.J Pathol. 2013 Aug;230(4):356-64.
  • Seo JH, Li Q, Fatima A, Eklund A, Szallasi Z, Polyak K, Richardson AL, Freedman ML.Deconvoluting complex tissues for expression quantitative trait locus-based analyses.Philos Trans R Soc Lond B Biol Sci. 2013;368(1620):20120363.
  • Baranyai Z, Mersich T, Dede K, Besznyák I, Zaránd A, Teknős D, Nagy P, Salamon F, Nagy P, Nagy Z, Kótai Z, Szász M, Lukács L, Szállási Z, Jósa V, Jakab F.[From project based sample collection to a biobank.].Orvosi Hetilap. 2011 Apr 1;152(15):606-609.
  • Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C.Chromosomal Instability Confers Intrinsic Multidrug Resistance.Cancer Res. 2011 Mar 1;71(5):1858-1870.
  • Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C.Paradoxical relationship between chromosomal instability and survival outcome in cancer.Cancer Res. 2011 Jan 26.
  • Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C.Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.PLoS ONE. 2010;5(12):e15031.
  • Burrell RA, Juul N, Johnston SR, Reis-Filho JS, Szallasi Z, Swanton C.Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.J Cell Biochem. 2010 Nov 1;111(4):782-90.
  • Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.Genome Med. 2010;2(8):53.
  • Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z.An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.Breast Cancer Res Treat. 2010 Oct;123(3):725-31.
  • Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C.Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.Lancet Oncol. 2010 Apr;11(4):358-65.
  • Eklund AC, Friis P, Wernersson R, Szallasi Z.Optimization of the BLASTN substitution matrix for prediction of non-specific DNA microarray hybridization.Nucleic Acids Res. 2010 Mar 1;38(4):e27.
  • Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.J Clin Oncol. 2010 Mar 1;28(7):1145-53.
  • Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC.Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.Nat Med. 2010 Feb;16(2):214-8.
  • Swanton C,Nicke B,Schuett M,Eklund AC,Ng C,Li Q,Hardcastle T,Lee A,Roy R,East P,Kschischo M,Endesfelder D,Wylie P,Kim SN,Chen JG,Howell M,Ried T,Habermann JK,Auer G,Brenton JD,Szallasi Z,Downward J.Chromosomal instability determines taxane response.Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6.
  • Lage K,Hansen NT,Karlberg EO,Eklund AC,Roque FS,Donahoe PK,Szallasi Z,Jensen TS,Brunak S.A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes.Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20870-5.
  • Lee AJ,East P,Pepper S,Nicke B,Szallasi Z,Eklund AC,Downward J,Swanton C.Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure.Cell Cycle. 2008 Dec 15;7(24):3947-8.
  • Swanton C,Szallasi Z,Brenton JD,Downward J.Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.Breast Cancer Res. 2008;10(5):214. Review.
  • Eklund AC, Szallasi Z.Correction of technical bias in clinical microarray data improves concordance with known biological information.Genome Biol. 2008;9(2):R26.
  • Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z.A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.Nat Genet. 2006 Sep;38(9):1043-8.
  • Carter SL, Eklund AC, Mecham BH, Kohane IS, Szallasi Z.Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements.BMC Bioinformatics. 2005;6:107.
  • Stelling J, Sauer U, Szallasi Z, Doyle FJ, Doyle J.Robustness of cellular functions.Cell. 2004 Sep 17;118(6):675-85.
  • Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P, Wetmore DZ, Mariani TJ, Kohane IS, Szallasi Z.Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements.Nucleic Acids Res. 2004;32(9):e74.